From Self-sufficiency
Jump to: navigation, search
File:Neratinib skeletal.svg
Systematic (IUPAC) name
Clinical data
Routes of
CAS Number 698387-09-6
ATC code none
PubChem CID 9915743
Chemical data
Formula C30H29ClN6O3
Molar mass 557.04 g/mol[[Script error: No such module "String".]]
Script error: No such module "collapsible list".
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Neratinib (HKI-272) is a tyrosine kinase inhibitor[1][2] under investigation for the treatment breast cancer[3] and other solid tumours.

Like lapatinib and BIBW 2992, it is a dual inhibitor of the human epidermal growth factor receptor 2 (Her2) and epidermal growth factor receptor (EGFR) kinases.[4]

Clinical trials

It will be included in the forthcoming I-SPY2 breast cancer trial.[5]


Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />

  1. "Definition of neratinib - National Cancer Institute Drug Dictionary". Retrieved 2008-12-01. 
  2. Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  3. NCT00398567 A Phase 1/2 Study Of HKI-272 In Combination With Herceptin In Subjects With Advanced Breast Cancer
  4. Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  5. "Breast cancer study aims to speed drugs, cooperation" March 2010